News ArchivesRead News

News Update for the Week of 4.27.20

Monday April 27, 2020
New Evidence that Parkinson's May Start in the Gut
Nature Genetics via MedicalXpress
Researchers at Karolinska Institutet in Sweden and the University of North Carolina analyzed differences in brain tissue from individual without Parkinson's and people with Parkinson's at different stages. They discovered that a type of support cell in the brain called oligodendrocytes were affected early on, suggesting that they play a key role in the early stages of Parkinson's.
"This makes them an attractive target for therapeutic interventions in Parkinson's," says Julien Bryois, researcher at the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet.
Neurocrine Gets U.S. Nod for Parkinson's Therapy;
COVID-19 Delays Launch
Neurocrine Biosciences Inc said on Monday its add-on treatment for patients with Parkinson’s, called Ongentys, received U.S. approval, but the launch will be delayed until later this year because of disruptions caused by the COVID-19 pandemic. Ongentys, chemically known as opicapone, belongs to a class of drugs which works by blocking an enzyme that breaks down levodopa in the body, helping extend the duration of its effect.
Parkinson Disease Primer - a True Team Effort
"Since the Primer was published, the field has not stood still and further exciting advances have been made, including refinements in our understanding of pathogenetic pathways and the genetic architecture of Parkinson's, notably, new evidence for prion-like propagation of misfolded α-synuclein as a driver of Parkinson's progression and intriguing findings suggesting gut-to-brain spreading.
Above all, several novel targets for disease-modifying therapies have evolved and are currently being evaluated in multiple randomized clinical trials6. The next decade will hopefully see some of these trials succeed and open the opportunity to link screening programs for Parkinson's risk with preventive interventions."